The prostate prognostic test was part of the ProstaGene acquisition. Yes $750M is an accurate estimate based on RP stating that 250,000 men have this test annually (total) and estimating $3,000 per test. This test is more accurate and could likely be priced higher, but 100% penetration is what the $750M figure is based on.

Like leronlimab, we don't have a sales force, so a license agreement seems likely. It requires FDA approval still, but based on my previous research these 510-k approval average around 5 months.